• #14: Citius Oncology's LYMPHIR™ Launch Strategy

  • Jan 10 2025
  • Length: 3 mins
  • Podcast

#14: Citius Oncology's LYMPHIR™ Launch Strategy

Listen for free

View show details

  • Summary

  • Citius Oncology is preparing to launch LYMPHIR™, a novel treatment for cutaneous T-cell lymphoma (CTCL), and is simultaneously exploring strategic options to maximize its market impact. These options include partnerships and acquisitions to bolster its position within the $400 million CTCL market. The company is focusing on a targeted launch strategy that includes patient support programs and securing international licensing agreements. Their aim is to provide patients with a much-needed therapy while increasing shareholder value. This launch follows years of development and regulatory hurdles.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about #14: Citius Oncology's LYMPHIR™ Launch Strategy

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available